Monoclonal antibodies development has been limited for a long time to only two species : mice and rats. However, the immune systems of mice and rats are not the most suitable in terms of humoral response to certain antigens, such as human antigens like glucagon. Indeed, the protein sequence of glucagon is the same in mice, rats and human (fig. 1). Small not immunogenic antigens, such as antibiotics or toxins, generally failed to trigger an immune response in such species. This is why some companies have developed fusion cell lines to generate monoclonal antibodies in rabbit (Abcam-Epitomics) or in sheep (Bioventix). However, these two tools are not totally satisfactory whether in terms of cost, stability or productivity.


SynAbs has therefore opted to develop its own myeloma cell line to manufacture guinea pig monoclonal antibodies and offer more efficient investigation tools for researchers.